The FDA escalated pressure on clinical-development sponsors to report results from registered studies, citing a compliance review that found results were missing for 30% of registered clinical studies. The agency sent reminders to roughly 2,200 entities, including drug companies, medical device manufacturers, and research groups. The FDA’s action highlights operational scrutiny around transparency and the timely disclosure of trial outcomes, affecting planning and reputational risk for sponsors with incomplete results dissemination. For trial programs with delayed reporting, the communication signals potential downstream enforcement scrutiny if noncompliance persists. The FDA did not change the fundamental statutory requirements in this reminder campaign, but the scale of the outreach indicates sustained focus on trial result reporting as an ongoing regulator priority.